PBK and neoplasm: In this study, small interfering RNA (siRNA) targeting PBK was chosen as the therapeutic agent, and nanotechnology was utilized to enhance its stability and bioavailability in vivo, thereby achieving specific responsiveness to the tumor microenvironment.